Grufity logoGrufity logo
StocksFundsSearch Filings

Haemonetics Corp Stock Research

HAE

83.21USD+0.33(+0.40%)Market Closed

Market Summary

USD83.21+0.33
Market Closed
0.40%

HAE Stock Price

HAE RSI Chart

HAE Valuation

Market Cap

4.2B

Price/Earnings (Trailing)

36.38

Price/Sales (Trailing)

3.72

EV/EBITDA

16.67

Price/Free Cashflow

25.77

HAE Price/Sales (Trailing)

HAE Profitability

EBT Margin

10.99%

Return on Equity

12.34%

Return on Assets

5.1%

Free Cashflow Yield

3.88%

HAE Fundamentals

HAE Revenue

Revenue (TTM)

1.1B

Revenue Y/Y

17.53%

Revenue Q/Q

2.63%

HAE Earnings

Earnings (TTM)

115.4M

Earnings Y/Y

201.64%

Earnings Q/Q

-10.81%

Price Action

52 Week Range

58.2391.39
(Low)(High)

Last 7 days

-1.1%

Last 30 days

1.1%

Last 90 days

5.5%

Trailing 12 Months

33.6%

HAE Financial Health

Current Ratio

3.11

HAE Investor Care

Buy Backs (1Y)

1.32%

Diluted EPS (TTM)

2.24

Peers (Alternatives to Haemonetics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
110.8B
19.0B
-8.78% 16.43%
46.98
6.01
8.73% 30.37%
107.5B
6.4B
4.05% 37.44%
81.96
16.72
8.89% -20.19%
74.1B
13.0B
-0.08% 27.20%
106.12
5.84
7.26% -32.95%
71.3B
18.8B
-6.73% -3.13%
44.09
3.79
-1.96% -15.83%
49.7B
5.5B
-6.18% -16.80%
33.38
9.03
2.68% -3.23%
MID-CAP
7.2T
557.2M
-1.64% 66.40%
82.2K
16.8K
86.42% 730.06%
11.7B
884.6M
7.85% 115.97%
1.8K
13.2
13.08% 200.12%
5.9B
1.1B
-8.20% -19.98%
34.14
5.75
11.20% 53.04%
3.6B
430.0M
-11.89% -12.63%
-34.73
8.45
26.13% 15.73%
1.7B
794.7M
-29.15% -60.56%
-8.43
2.16
7.73% -3556.34%
SMALL-CAP
1.6B
389.0M
-3.76% 82.19%
-10.63
4.18
44.08% 6.96%
1.2B
150.7M
-30.80% 0.49%
-21.65
7.87
40.31% 1.80%
1.1B
814.3M
-20.14% -16.22%
24.47
1.34
6.96% 121.89%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%

Financials for Haemonetics

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue4.2%1,1291,0841,026993953
Gross Profit3.5%595575540506-
Operating Expenses2.8%455443430425-
  S&GA Expenses3.9%371357341340-
  R&D Expenses5.9%48.0045.0045.0047.00-
EBITDA4.8%218208187168-
EBITDA Margin0.6%0.19*0.19*0.18*0.17*-
Earnings Before Taxes9.6%12411392.0064.00-
EBT Margin5.1%0.11*0.10*0.09*0.06*-
Interest Expenses-6.00----
Net Income11.3%96.0086.0068.0043.00-
Net Income Margin6.8%0.08*0.08*0.07*0.04*-
Free Cahsflow10.1%12811688.0076.00-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets3.0%1,9351,8781,8651,8211,860
  Current Assets9.0%770706716688756
    Cash Equivalents27.0%284224241215259
  Inventory1.4%259256255278293
  Net PPE-0.7%311313308288258
  Goodwill0.0%466466465466467
  Current Liabilities11.0%252227262180442
    LT Debt, Current18.4%12.0010.0058.007.00214
    LT Debt, Non Current-0.4%754757760763559
Shareholder's Equity5.4%818776729770749
  Retained Earnings13.1%253224204222202
  Additional Paid-In Capital1.2%595587564580572
Shares Outstanding0.0%50.0050.0051.0051.0051.00
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations4.4%273261260216172
  Share Based Compensation8.3%26.0024.0023.0023.0024.00
Cashflow From Investing10.3%-143-160-139-128-86.34
Cashflow From Financing6.7%-100-107-59.88-37.51-15.75
  Buy Backs-25.0%75.001001000.00-

Risks for HAE

What is the probability of a big loss on HAE?

80.4%


Probability that Haemonetics stock will be more than 20% underwater in next one year

53.1%


Probability that Haemonetics stock will be more than 30% underwater in next one year.

28.1%


Probability that Haemonetics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does HAE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Haemonetics was unfortunately bought at previous high price.

Drawdowns

Returns for HAE

Cumulative Returns on HAE

7.1%


10-Year Cumulative Returns

16.8%


7-Year Cumulative Returns

-1.7%


5-Year Cumulative Returns

-8.3%


3-Year Cumulative Returns

What are the long-term rolling returns for HAE?

FIve years rolling returns for Haemonetics.

Annualized Returns

Which funds bought or sold HAE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-23
ROYCE & ASSOCIATES LP
added
2.22
4,898,060
69,820,600
0.70%
2023-05-23
Toroso Investments, LLC
added
10.49
72,000
516,000
0.01%
2023-05-22
American Trust
sold off
-100
-207,636
-
-%
2023-05-22
AMERIPRISE FINANCIAL INC
added
3.22
3,014,030
38,085,000
0.01%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
added
21.13
1,111,000
5,161,000
0.01%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
unchanged
-
210,000
8,022,000
0.01%
2023-05-18
JPMORGAN CHASE & CO
added
16.11
2,672,000
14,721,000
-%
2023-05-17
Advisory Services Network, LLC
added
2.59
1,687
22,922
-%
2023-05-17
VIRGINIA RETIREMENT SYSTEMS ET AL
added
76.53
635,151
1,360,640
0.01%
2023-05-17
Thrivent Financial for Lutherans
reduced
-1.23
42,000
1,102,000
-%

1–10 of 41

Latest Funds Activity

Are funds buying HAE calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own HAE
No. of Funds

Haemonetics News

MarketBeat
Zions Bancorporation N.A. Purchases 1954 Shares of Haemonetics ....
MarketBeat,
14 hours ago
Nasdaq
Seeking Alpha
Yahoo Finance

Schedule 13G FIlings of Haemonetics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital research global investors
11.8%
5,956,064
SC 13G/A
Feb 09, 2023
vanguard group inc
10.36%
5,242,836
SC 13G/A
Feb 06, 2023
wellington management group llp
7.97%
4,034,753
SC 13G/A
Jan 26, 2023
blackrock inc.
11.7%
5,898,620
SC 13G/A
Jan 20, 2023
blackrock inc.
11.7%
5,898,620
SC 13G/A
Apr 08, 2022
capital research global investors
10.7%
5,452,006
SC 13G
Feb 14, 2022
neuberger berman group llc
7.59%
3,876,521
SC 13G/A
Feb 11, 2022
capital research global investors
4.0%
2,049,133
SC 13G/A
Feb 10, 2022
vanguard group inc
9.55%
4,880,936
SC 13G/A
Feb 10, 2022
wellington management group llp
10.83%
5,537,538
SC 13G/A

HAE Fair Value

Recent SEC filings of Haemonetics

View All Filings
Date Filed Form Type Document
May 22, 2023
10-K
Annual Report
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 19, 2023
4
Insider Trading
May 17, 2023
4
Insider Trading
May 17, 2023
4
Insider Trading
May 17, 2023
4
Insider Trading

Latest Insider Trading transactions for HAE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-18
Miller Laurie A.
sold (taxes)
-7,500
83.34
-90.00
svp, human resources
2023-05-18
Basil Michelle L
sold (taxes)
-295,107
83.34
-3,541
evp and general counsel
2023-05-18
Strong Stewart W
sold (taxes)
-90,590
83.34
-1,087
president, global hospital
2023-05-18
Simon, Christopher
sold (taxes)
-319,942
83.34
-3,839
president & ceo
2023-05-18
Lingamneni Anila
sold (taxes)
-115,426
83.34
-1,385
evp, chief technology officer
2023-05-18
Llorens Josep
sold (taxes)
-118,593
83.34
-1,423
evp, global manufacturing
2023-05-16
Basil Michelle L
sold (taxes)
-39,787
89.21
-446
evp and general counsel
2023-05-16
Simon, Christopher
sold (taxes)
-141,487
89.21
-1,586
president & ceo
2023-05-16
Lingamneni Anila
sold (taxes)
-28,368
89.21
-318
evp, chief technology officer
2023-05-16
Strong Stewart W
sold (taxes)
-22,302
89.21
-250
president, global hospital

1–10 of 50

Christopher A. Simon
2710
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

HAE Income Statement

2023-04-01
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Apr. 01, 2023
Apr. 02, 2022
Apr. 03, 2021
Income Statement [Abstract]   
Net revenues$ 1,168,660$ 993,196$ 870,463
Cost of goods sold553,563487,694472,625
Gross profit615,097505,502397,838
Operating expenses:   
Research and development50,13146,80132,857
Selling, general and administrative376,675340,140275,216
Amortization of acquired intangible assets32,64047,41432,830
Gains on divestitures and sale of assets(382)(9,603)(32,812)
Total operating expenses459,064424,752308,091
Operating income156,03380,75089,747
Interest and other expense, net(14,630)(17,121)(16,834)
Income before provision (benefit) for income taxes141,40363,62972,913
Provision (benefit) for income taxes26,00220,254(6,556)
Net income$ 115,401$ 43,375$ 79,469
Net income per share - basic (in dollars per share)$ 2.27$ 0.85$ 1.57
Net income per share - diluted (in dollars per share)$ 2.24$ 0.84$ 1.55
Weighted average shares outstanding   
Basic (in shares)50,78351,04750,688
Diluted (in shares)51,42051,35351,292

HAE Balance Sheet

2023-04-01
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Apr. 01, 2023
Apr. 02, 2022
Current assets:  
Cash and cash equivalents$ 284,466$ 259,496
Accounts receivable, less allowance for credit losses of $4,932 at April 1, 2023 and $2,475 at April 2, 2022179,142159,376
Inventories, net259,379293,027
Prepaid expenses and other current assets46,73544,132
Total current assets769,722756,031
Property, plant and equipment, net310,885258,482
Intangible assets, less accumulated amortization of $417,422 at April 1, 2023 and $376,552 at April 2, 2022275,771310,261
Goodwill466,231467,287
Deferred tax asset5,2414,468
Other long-term assets106,97563,205
Total assets1,934,8251,859,734
Current liabilities:  
Notes payable and current maturities of long-term debt11,784214,148
Accounts payable63,92958,371
Accrued payroll and related costs64,47548,540
Other current liabilities111,628121,207
Total current liabilities251,816442,266
Long-term debt, net of current maturities754,102559,441
Deferred tax liability36,19528,727
Other long-term liabilities74,71579,876
Stockholders’ equity:  
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 50,448,519 shares at April 1, 2023 and 51,124,240 shares at April 2, 2022504511
Additional paid-in capital594,706572,476
Retained earnings253,168202,391
Accumulated other comprehensive loss(30,381)(25,954)
Total stockholders’ equity817,997749,424
Total liabilities and stockholders’ equity$ 1,934,825$ 1,859,734